文献速递认知障碍与痴呆

行为变异型额颞叶痴呆患者血清神经丝轻链蛋白研究

Serum neurofilament light chain in behavioral variant frontotemporal dementia.
PubMed 文献 · Neurology · 2018-09-12

该研究纳入74例行为变异型额颞叶痴呆(bvFTD)、26例阿尔茨海默病(AD)、17例轻度认知障碍(MCI)和15名健康对照,测定基线和随访血清神经丝轻链蛋白(NfL),分析其与功能评估和脑萎缩的关联。结果显示血清NfL在bvFTD最高,与功能评分和多个脑区萎缩相关。

要点

  • bvFTD患者血清NfL水平高于健康对照、MCI和AD患者。
  • 血清NfL鉴别bvFTD与对照/MCI/AD的敏感性为91%/74%/74%,特异性为79%/74%/58%。
  • 随访中bvFTD和AD患者血清NfL均升高(p=0.0039和p=0.0006)。

核心结论

  • 血清NfL在不同疾病阶段与bvFTD的功能损害和脑萎缩相关,作者提出其可作为疾病严重程度的标志物,为未来用作临床试验结局指标铺平道路。

研究设计与样本

  • 研究纳入74例bvFTD、26例AD、17例MCI患者和15名健康对照,测定基线和随访血清NfL水平。
  • 分析血清NfL与脑脊液NfL、功能评估(CDR-SOB、额颞叶变性相关CDR-SOB、MMSE)和脑 volumetry 的关联。

主要发现

  • 基线血清NfL与脑脊液NfL相关(bvFTD r=0.706,p<0.0001;AD/MCI r=0.666,p=0.0003)。
  • 血清NfL水平在bvFTD最高(与对照和MCI比较p<0.0001,与AD比较p=0.0078)。
  • 血清NfL鉴别bvFTD与对照/MCI/AD的敏感性为91%/74%/74%,特异性为79%/74%/58%。
  • 随访中血清NfL在bvFTD和AD升高(分别为p=0.0039和p=0.0006)。
  • 基线和随访NfL与bvFTD功能评分相关(如CDR-SOB基线r=0.4157,p=0.0006;随访r=0.5629,p<0.0001),并与包括额叶和皮层下区域在内的灰质和白质萎缩相关(如额叶r=-0.5857,p<0.0001,95%CI -0.7415至-0.3701)。

关键数值与推荐

  • 研究提供III级证据:对于有认知问题的患者,血清NfL浓度可鉴别bvFTD与其他形式痴呆。

临床怎么用

  • 作者提出血清NfL可作为bvFTD疾病严重程度的标志物,并为其未来用作临床试验结局指标铺平道路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD). METHODS: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration-related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry. RESULTS: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = -0.5857, p < 0.0001; 95% confidence interval -0.7415 to -0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes. CONCLUSIONS: As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Steinacker P, Anderl-Straub S, Diehl-Schmid J, et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018. PMID: 30209235. doi:10.1212/WNL.0000000000006318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。